9 Results for "

Biliary tract cancer

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Biliary tract cancer" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-129523
CAS No.: 2378258-52-5
Purity:  95.66%
Target:  

PROTACs Ras

Research Areas:  

Cancer

PROTAC K-Ras Degrader-1 is a K-Ras PROTAC degrader. It binds to both K-Ras and the Cereblon E3 ubiquitin ligase, bringing K-Ras into proximity with the ligase, thereby achieving its degradation and inhibition. PROTAC K-Ras Degrader-1 can be used for research in various cancers .
loading...
    loading...
Cat. No.: HY-P991564
CAS No.: 3031170-61-0
Synonyms: IBI-343 antibody; HB37A6; TAK-921 Antibody

Target:  

ADC Antibodies Claudin

Research Areas:  

Cancer

Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .
loading...
    loading...
Cat. No.: HY-153821
CAS No.: 2378257-72-6
Purity:  98.45%
Target:  

PROTACs Ras

Research Areas:  

Cancer

PROTAC KRAS G12C (Compound 432) degrader-2 is a PROTAC degrader that targets KRAS G12C by recruiting cereblon. PROTAC KRAS G12C degrader-2 covalently modifies KRAS G12C. PROTAC KRAS G12C degrader-2 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P990059
CAS No.: 2760250-47-1
Synonyms: INT-016; AZD8205 Antibody

Research Areas:  

Cancer

Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .
loading...
    loading...
Cat. No.: HY-201296A
CAS No.: 17515-36-5
Synonyms: TUCA sodium
Target:  

Drug Isomer

Research Areas:  

Cancer

Tauroursocholic acid (TUCA) sodium is a taurine-conjugated form of the bile acid ursocholic acid and the 7β-hydroxy epimer of Taurocholic acid (HY-B1788). Tauroursocholic acid sodium exists in abundance during the biliary tract cancer, disrupting the balance and cellular toxicity of bile acids and inducing carcinogenesis through oxidative DNA damage and DNA mutation. Tauroursocholic acid (TUCA) sodium can be used for biliary tract cancer research .
loading...
    loading...
Cat. No.: HY-P992021

Research Areas:  

Cancer

WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer .
loading...
    loading...
Cat. No.: HY-183947
CAS No.: 56943-06-7
Research Areas:  

Cancer

4-Bromolevamisole, an analogues of Levamisole (HY-A0106), is a phosphatase inhibitor. 4-Bromolevamisole potentiates the antineoplastic activity of 5-Fluorouracil (HY-90006), its analogues, or prodrugs thereof.4-Bromolevamisole can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P992454

Target:  

Tim3

Research Areas:  

Cancer

S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 + T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .
loading...
    loading...
Cat. No.: HY-184371
CAS No.: 2907719-42-8
Research Areas:  

Cancer

MC-GGFG-Eribulin is a linker-payload of a tubulin inhibitor-based cytotoxic agent with an N-substituted maleimide group, conjugated via the MC-GGFG linker. MC-GGFG-Eribulin reacts with the thiol groups of reduced antibodies or antigen-binding fragments to form antibody-drug conjugates. MC-GGFG-Eribulin is applicable for cancer-related research .
loading...
    loading...